Info@ThinkPinkRocks.com

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

See more here:
DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Share

Leave a Reply

Solve : *
11 + 13 =